FrancophonIA/ELRC3.0 huggingface dataset:
English: HCV/HIV Co-infected patients
Estonian: Laboratoorsed näitajad HCV/HIV koinfitseerunud patsientidel
English: − chest discomfort, difficult breathing, lung infection, nasal discomfort, pneumonia,wheezing,
Estonian: kihelustunne silmades, näopiirkonna valu, põletikulised igemed, - ebamugavustunne rinnus, hingamisraskused, kopsuinfektsioon, ebamugavustunne ninas,
English: Ribavirin (800 mg/day) + interferon alfa2b (3 MIU TIW)
Estonian: alfa-2b-interfer oon (3 MRÜ TIW)
English: Pruritus, photosensitivity reaction, maculopapular rash, eczema, hyperhidrosis, acne, skin disorder, nail disorder, skin discolouration, dry skin, erythema, bruise
Estonian: Kihelus, valgustundlikkusreaktsioon, makulopapuloosne lööve, ekseem, hüperhidroos, akne, nahakahjustus, küüne kahjustus, naha värvusetuks muutumine, nahakuivus, erüteem, verevalum
English: Please refer to the corresponding SmPC of medicinal products used in combination with Ribavirin Teva for contraindications specific to these products.
Estonian: Kui Ribavirin Teva'ga kasutatakse koos teisi ravimeid, lugege palun vastavat ravimi omaduste kokkuvõtet.
English: Do not take a double dose to make up for a forgotten dose
Estonian: Ärge võtke kahekordset annust, kui annus jäi eelmisel korral võtmata.
English: This summary was last updated in 02-2011.
Estonian: Kokkuvõtte viimane uuendus: 02-2011.
English: The marketing authorisation holder is Generics [UK] Ltd.
Estonian: Müügiloa hoidja on Generics [UK] Ltd.
English: EPAR summary for the public
Estonian: Kokkuvõte üldsusele ribaviriin
English: The name of the medicine was changed to Ribavirin Mylan on 27 January 2011.
Estonian: Ravimi nimetus muudeti Ribavirin Mylanks 27 Jaanuar 2011.
English: Ribavirin Mylan can also be used in adults whose disease has come back after previous treatment or whose previous treatment failed.
Estonian: Ravimit Ribavirin Mylan võib kasutada ka täiskasvanud patsientidel, kelle haigus on pärast eelmist ravi taastunud või kellele varasem ravi ei ole mõjunud.
English: Ribavirin Mylan is taken with food each day in two divided doses (morning and evening).
Estonian: Ravimit Ribavirin Mylan manustatakse iga päev koos toiduga, jagades annuse kahte ossa (hommikune ja õhtune annus).
English: Ribavirin Mylan must never be used on its own but only together with interferon alfa-2b (another medicine used in hepatitis).
Estonian: Ravimit Ribavirin Mylan ei tohi kunagi kasutada ainsa ravimina, vaid ainult koos alfa-2b-interferooniga (samuti hepatiidiravim).
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Ribavirin Mylan.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: This document is a summary of the European Public Assessment Report (EPAR) for Ribavirin Mylan.
Estonian: Käesolev dokument on ravimi Ribavirin Mylan Euroopa avaliku hindamisaruande kokkuvõte.
English: Ribavirin Mylan is thought to interfere with the production or action of viral DNA and RNA, which are needed for viruses to survive and multiply.
Estonian: Arvatakse, et Ribavirin Mylan häirib viiruste püsimiseks ja paljunemiseks vajaliku viiruse-DNA ja -RNA teket või toimet.
English: For more information about treatment with Ribavirin Mylan, read the Package Leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate ravimiga Ribavirin Mylan toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Ribavirin Mylan on its own has no effect on eliminating the hepatitis C virus from the body.
Estonian: Ribavirin Mylan ainsa ravimina ei mõjuta C-hepatiidi viiruse kõrvaldamist organismist.
English: Because Ribavirin Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine.
Estonian: Et Ribavirin Mylan on geneeriline ravim ja bioekvivalentne võrdlusravimitega, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimitel.
English: This means that Ribavirin Mylan is similar to a ‘reference medicine' already authorised in the European Union (EU) called Rebetol.
Estonian: See tähendab, et Ribavirin Mylan on sarnane võrdlusravimiga Rebetol, millel juba on Euroopa Liidus müügiluba.
English: It can only be used in patients who weigh more than 47 kg.
Estonian: Ravimit saab kasutada ainult patsientidel, kes kaaluvad vähemalt
English: The Committee recommended that Ribavirin Mylan be given marketing authorisation.
Estonian: Komitee soovitas anda ravimi Ribavirin Mylan müügiloa.
English: The European Commission granted a marketing authorisation valid throughout the EU for Ribavirin Three Rivers on 10 June 2010.
Estonian: Euroopa Komisjon andis ravimi Ribavirin Three Rivers müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Ribavirin Three Rivers.
English: Ribavirin Mylan is a medicine that contains the active substance ribavirin.
Estonian: Ribavirin Mylan on ravim, mis sisaldab toimeainena ribaviriini.
English: Because Ribavirin Mylan is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Rebetol.
Estonian: Et Ribavirin Mylan on geneeriline ravim, piirdusid uuringud katsetega, milles näidati ravimi Ribavirin BioPartners bioekvivalentsust võrdlusravimiga Rebetol.
English: Ribavirin Mylan is used to treat long-term hepatitis C (a disease of the liver due to infection with the hepatitis C virus) in patients aged three years and older.
Estonian: Ravimit Ribavirin Mylan kasutatakse kroonilise (pikaajalise) C-hepatiidi (C-hepatiidi viiruse nakkusest põhjustatud maksahaigus) raviks vähemalt 3-aastastel patsientidel.
English: Why has Ribavirin Mylan been approved?
Estonian: Miks Ribavirin Mylan heaks kiideti?
English: Ribavirin Mylan is a ‘generic medicine'.
Estonian: Ribavirin Mylan on geneeriline ravim.
English: The CHMP concluded that, in accordance with EU requirements, Ribavirin Mylan has been shown to have comparable quality and to be bioequivalent to Rebetol.
Estonian: Inimravimite komitee otsustas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Ribavirin Mylan võrdväärne kvaliteet ja bioekvivalentsus ravimiga Rebetol.
English: What is Ribavirin Mylan?
Estonian: Mis on Ribavirin Mylan?
English: Ribavirin Mylan is used in patients who have not been treated before, as long as the liver is still working and hepatitis C virus can be found in the blood.
Estonian: Ravimit kasutatakse varem ravimata C-hepatiidiga patsientide raviks, kelle maks veel toimib ja kelle veres on C-hepatiidi viirust.
English: The active substance in Ribavirin Mylan, ribavirin, is an antiviral belonging to the class ‘nucleoside analogues'.
Estonian: Ravimi Ribavirin Mylan toimeaine ribaviriin on nukleosiidianaloogide klassi kuuluv viiruseravim.
English: Treatment with Ribavirin Mylan should be started and monitored by a doctor who has experience in the management of long-term hepatitis C. The dose of Ribavirin Mylan is based on the patient's body weight, and ranges from three to seven capsules a day.
Estonian: Ravimi Ribavirin Mylan annus põhineb patsiendi kehakaalul ja on 3-7 kapslit päevas.
English: Other information about Ribavirin Mylan:
Estonian: Muu teave ravimi Ribavirin Mylan kohta
English: The full EPAR for Ribavirin Mylan can be found here.
Estonian: Euroopa avaliku hindamisaruande täistekst ravimi Ribavirin Mylan kohta on siin.
English: How has Ribavirin Mylan been studied?
Estonian: Kuidas ravimit Ribavirin Mylan uuriti?
English: How is Ribavirin Mylan used?
Estonian: Kuidas ravimit Ribavirin Mylan kasutatakse?
English: What are the benefit and risk of Ribavirin Mylan?
Estonian: Milles seisneb ravimi Ribavirin Mylan kasulikkus ja mis riskid ravimiga kaasnevad?
English: What is Ribavirin Mylan used for?
Estonian: Milleks ravimit Ribavirin Mylan kasutatakse?
English: What measures are being taken to ensure the safe and effective use of Solymbic?
Estonian: Mis meetmed võetakse, et tagada Solymbici ohutu ja efektiivne kasutamine?
English: Other information about Solymbic
Estonian: Muu teave Solymbici kohta
English: The full EPAR for Solymbic can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Solymbici kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Solymbic adalimumab
Estonian: Solymbic adalimumaab
English: After the starting dose, Solymbic is most often given every two weeks, but it may be given every week in certain situations.
Estonian: Pärast algannust manustatakse Solymbici tavaliselt iga kahe nädala järel, kuid teatud olukordades tohib Solymbici manustada iga nädal.
English: After training, patients or their carers may inject Solymbic if their doctor considers it appropriate.
Estonian: Patsiendid või nende hooldajad võivad pärast asjakohase väljaõppe saamist süstida Solymbici ise, kui arst peab seda kohaseks.
English: Solymbic is mostly used in adults when their conditions are severe, moderately severe or getting worse, or when patients cannot use other treatments.
Estonian: Solymbici kasutatakse enamasti raskes, mõõdukalt raskes või halvenevas seisundis täiskasvanutel või kui patsiendid ei saa muid ravimeid kasutada.
English: What is Solymbic and what is it used for?
Estonian: Mis on Solymbic ja milleks seda kasutatakse?
English: This means that Solymbic is highly similar to a biological medicine (also known as the ‘reference medicine') that is already authorised in the European Union (EU).
Estonian: See tähendab, et Solymbic sarnaneb bioloogilise ravimiga (võrdlusravimiga), millel juba on Euroopa Liidus müügiluba.
English: Because Solymbic is a biosimilar medicine, the studies on effectiveness and safety carried out for Humira do not all need to be repeated for Solymbic.
Estonian: Et Solymbic on bioloogiliselt sarnane ravim, ei pea kõiki Humiraga tehtud efektiivsus- ja ohutusuuringuid Solymbiciga kordama.
English: Patients may be given other medicines during treatment with Solymbic, such as methotrexate or corticosteroids (other anti‑inflammatory medicines).
Estonian: Solymbici ravi ajal võib patsientidele manustada ka muid ravimeid, näiteks metotreksaati või kortikosteroide (samuti põletikuvastased ravimid).
English: Why is Solymbic approved?
Estonian: Miks Solymbic heaks kiideti?
English: This is a summary of the European public assessment report (EPAR) for Solymbic.
Estonian: See on ravimi Solymbic Euroopa avaliku hindamisaruande kokkuvõte.
English: Solymbic is a medicine that acts on the immune system and is used to treat the following conditions:
Estonian: Solymbic on immuunsüsteemi ravim ja seda kasutatakse järgmiste haiguste korral:
English: The medicine has been shown to have similar effects to Humira in one main study involving 526 patients with moderate to severe rheumatoid arthritis that had not responded adequately to methotrexate, and in another study in 350 patients with moderate to severe psoriasis.
Estonian: Solymbici Humira toimega võrreldavat toimet tõendati ühes põhiuuringus 526-l mõõduka kuni raske reumatoidartriidiga patsiendil, kellel metotreksaadiga ei olnud tekkinud piisavat ravivastust, ning veel ühes uuringus, milles osales 350 mõõduka kuni raske psoriaasiga patsienti.
English: The Committee recommended that Solymbic be given marketing authorisation.
Estonian: Komitee soovitas anda ravimile Solymbic müügiloa.
English: Solymbic must not be used in patients with active tuberculosis or other severe infections, or in patients with moderate to severe heart failure (an inability of the heart to pump enough blood around the body).
Estonian: Solymbici ei tohi kasutada aktiivse tuberkuloosi, muu raske infektsiooni ja mõõduka kuni raske südamepuudulikkusega patsiendid (kelle süda ei suuda pumbata organismi piisaval hulgal verd).
English: Other rare serious side effects (seen in between 1 in 10,000 and 1 in 1,000 patients) include failure of bone marrow to produce blood cells, disorder of the nerves, lupus and lupus-like conditions (where the immune system attacks the patient's own tissues, causing inflammation and organ damage), and Stevens-Johnson syndrome (a serious skin condition).
Estonian: Muud harvad rasked kõrvalnähud (esinenud 1-10 000 patsiendil ning 1 patsiendil 1000st) on muu hulgas luuüdi suutmatus toota vererakke, närvihäired, luupus ja luupuselaadne seisund (immuunsüsteem ründab patsiendi enda kudesid, mis põhjustab põletikku ja kahjustab organeid) ja Stevensi-Johnsoni sündroom (raske nahahaigus).
English: It is not intended to provide practical advice on how to use Solymbic.
Estonian: Hindamisaruandes ei anta Solymbici kasutamise praktilisi nõuandeid.
English: The most common side effects with adalimumab (seen in more than 1 patient in 10) are infections in the nose and throat, sinuses and upper respiratory tract, injection site reactions (redness, itching, bleeding, pain or swelling), headache and muscle and bone pain.
Estonian: Solymbici kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on nina-neelu-, nina kõrvalurgete ja ülemiste hingamisteede infektsioonid, süstekoha reaktsioonid (punetus, sügelus, verejooks, valu või turse), peavalu ning lihase- ja luuvalu.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Solymbic have also been included in the summary of product characteristics and the package leaflet.
Estonian: Solymbici ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: The reference medicine for Solymbic is Humira.
Estonian: Solymbici võrdlusravim on Humira.
English: In addition, studies in rheumatoid arthritis and psoriasis have shown that the effects of the medicine are equivalent to those of Humira in these conditions.
Estonian: Peale selle on reumatoidartriidi ja psoriaasi uuringutes tõendatud, et Solymbici toime on kõnealuste seisundite korral võrreldav Humira toimega.
English: All these data were considered sufficient to conclude that Solymbic will behave in the same way as Humira in terms of effectiveness and safety in its approved indications.
Estonian: Nende piisavate andmete põhjal järeldati, et Solymbici efektiivsus ja ohutus on heakskiidetud näidustustel võrreldav Humira efektiivsuse ja ohutusega.
English: This messenger is involved in causing inflammation and is found at high levels in patients with the diseases that Solymbic is used to treat.
Estonian: See virgatsaine osaleb põletiku tekitamisel ning selle sisaldus on suur patsientidel, kelle haigusi ravitakse Solymbiciga.
English: What are the risks associated with Solymbic?
Estonian: Mis riskid Solymbiciga kaasnevad?
English: For information on the doses to be used for each condition and other information on the use of Solymbic, see the package leaflet.
Estonian: Iga ravitava seisundi korral kasutatavate annuste teave ja muu teave Solymbici kasutamise kohta on pakendi infolehel.
English: For the full list of restrictions with Solymbic, see the package leaflet.
Estonian: Solymbici kohta teatatud piirangute täielik loetelu on pakendi infolehel.
English: Solymbic and other medicines of its class may also affect the ability of the immune system to fight off infections and cancer, and there have been some cases of serious infections and blood cancers in patients using adalimumab.
Estonian: Solymbic ja teised sama klassi ravimid võivad mõjutada ka immuunsüsteemi võimet võidelda infektsioonide ja vähiga (adalimumaabi kasutanud patsientide seas on esinenud raske infektsiooni või verevähi juhtumeid).
English: How does Solymbic work?
Estonian: Kuidas Solymbic toimib?
English: Solymbic can only be obtained with a prescription and treatment should be started and supervised by specialist doctors experienced in the diagnosis and treatment of the conditions for which it is authorised.
Estonian: Solymbic on retseptiravim ning ravi sellega peavad alustama ja jälgima näidustatud seisundite diagnoosimises ja ravis kogenud eriarstid.
English: In the rheumatoid arthritis study, response was measured as a 20% or more improvement in symptom score after 24 weeks of treatment: 75% of those given Solymbic responded, compared with 72% of those given Humira.
Estonian: Reumatoidartriidi uuringus loeti ravivastuseks sümptomite skoori vähemalt 20%-list paranemist pärast 24 ravinädalat - Solymbici saanud patsientidest saavutas ravivastuse 75% ja Humirat saanud patsientidest 72%.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that, in accordance with EU requirements for biosimilar medicines, Solymbic has a highly similar structure, purity and biological activity to Humira and is distributed in the body in the same way.
Estonian: Inimravimite komitee otsustas, et vastavalt Euroopa Liidu nõuetele bioloogiliselt sarnaste ravimite kohta on tõendatud, et Solymbic sarnaneb struktuuri, puhtuse ja bioloogilise toime poolest Humiraga ning et Solymbic jaotub organismis samamoodi kui Humira.
English: In the psoriasis study, which looked at the degree of improvement after 16 weeks, there was an 81% improvement in symptom score with Solymbic compared with an 83% improvement with Humira.
Estonian: Psoriaasiuuringus, milles uuriti paranemismäära pärast 16 ravinädalat, paranes sümptomite skoor Solymbici saanud patsientidest 81%-l ja Humirat saanud patsientidest 83%-l.
English: Extensive laboratory studies comparing Solymbic with Humira have shown that adalimumab in Solymbic is highly similar to adalimumab in Humira in terms of chemical structure, purity and biological activity.
Estonian: Ulatuslikes laboriuuringutes, kus Solymbici võrreldi Humiraga, selgus, et Solymbici toimeaine adalimumaab on keemilise struktuuri, puhtuse ja bioloogilise toime poolest äärmiselt sarnane Humiras sisalduva adalimumaabiga.
English: Doctors treating uveitis should also take advice from doctors who have experience of using Solymbic.
Estonian: Uveiiti ravivad arstid peaksid ühtlasi konsulteerima Solymbici kasutamise kogemusega spetsialistiga.
English: For practical information about using Solymbic, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Solymbici kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: For detailed information on the use of Solymbic in all conditions, including when it can be used in children, see the summary of product characteristics (also part of the EPAR).
Estonian: Üksikasjalik teave Solymbici kasutamise kohta kõigi nende seisundite raviks, sealhulgas lastel, on ravimi omaduste kokkuvõttes (mis on samuti Euroopa avaliku hindamisaruande osa).
English: • axial spondyloarthritis (inflammation of spine causing back pain), including ankylosing spondylitis and when there is no damage on X-ray but clear signs of inflammation
Estonian: • aksiaalne spondüloartriit (seljavalu põhjustav lülisambapõletik), sealhulgas jäigastav spondüliit, kui röntgeniuuring ei näita kahjustusi, kuid on selged põletikunähud;
English: The company that markets Solymbic must provide educational packs for doctors who will prescribe the medicine.
Estonian: Solymbici turustaja annab Solymbici määravatele arstidele teabematerjali.
English: For more information about treatment with Solymbic, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Solymbiciga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: How is Solymbic used?
Estonian: Kuidas Solymbici kasutatakse?
English: Solymbic contains the active substance adalimumab and is a ‘biosimilar medicine'.
Estonian: Solymbic sisaldab toimeainena adalimumaabi ja on bioloogiliselt sarnane ravim.
English: What benefits of Solymbic have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Solymbici kasulikkus?
English: The active substance in Solymbic, adalimumab, is a monoclonal antibody (a type of protein) that has been designed to recognise and attach to a chemical messenger in the body called tumour necrosis factor (TNF).
Estonian: Solymbici toimeaine adalimumaab on monoklonaalne antikeha (teatud valk), mis tunneb ära organismis leiduva virgatsaine kasvaja nekroositeguri (TNF) ja seondub sellega.
English: Therefore, the CHMP's view was that, as for Humira, the benefit outweighs the identified risk.
Estonian: Seetõttu on inimravimite komitee arvamusel, et nagu ka Humira korral, ületab ravimi Solymbic kasulikkus sellega kaasnevad riskid.
English: The medicine is available as a solution for injection under the skin in a pre-filled syringe or pen.
Estonian: Solymbici turustatakse naha alla süstitava lahusena eeltäidetud süstlis või pen-süstlis.
English: • active enthesitis-related arthritis (a rare disease causing inflammation in the joints)
Estonian: • aktiivne entesiidiga seotud artriit (liigesepõletikku põhjustav harvaesinev haigus);
English: 400 mg / 100 mg / 100 mg Film-coated tablet Oral use bottle (HDPE)
Estonian: 400 mg / 100 mg/ 100 mg
English: Pharmaceutical Form
Estonian: Ravimvorm Manustamistee Sisepakend
English: Invented name Strength
Estonian: Ravimi väljamõeldud nimetus Tugevus
English: Pharmaceutical Form Route of Administration Packaging
Estonian: Ravimvorm Manustamistee Pakendi iseloomustus Pakendi sisu Pakendi suurus
English: See also information under the heading “Do not take Karvea”.
Estonian: Vt ka teavet lõigus „Ärge võtke Karvea't”.
English: Karvea should not be given to children under 18 years of age.
Estonian: Karvea't ei tohi anda lastele ja noorukitele vanuses kuni 18 aastat.
English: You can take Karvea with or without food.
Estonian: Karvea'i võib võtta kas koos toiduga või ilma.
English: The safety and efficacy of Karvea in children aged 0 to 18 has not been established.
Estonian: Karvea ohutus ja efektiivsus lastel vanuses 0 kuni 18 aastat ei ole veel tõestatud.
English: It is important that you continue to take Karvea until your doctor tells you otherwise.
Estonian: Oluline on kasutada Karvea'i nii kaua kuni arst ei ole otsustanud teisiti.
English: Some undesirable effects have been reported since marketing of Karvea.
Estonian: Mõnedest kõrvaltoimetest on teatatud Karvea'i turustamisjärgselt.
English: Therefore, the use of Karvea is not recommended.
Estonian: Seetõttu ei ole Karvea kasutamine soovitatav.
English: The efficacy of Karvea is not influenced by age or gender.
Estonian: Karvea efektiivsust ei mõjuta vanus või sugu.
English: Please see section 2 “Karvea contains lactose”.
Estonian: Vt lõik 2, „Karvea sisaldab laktoosi“.
English: Karvea contains lactose.
Estonian: Karvea sisaldab laktoosi.
English: If you forget to take Karvea
Estonian: Kui te unustate Karvea't võtta
English: What you need to know before you take Karvea
Estonian: Mida on vaja teada enne Karvea võtmist
English: What Karvea is and what it is used for
Estonian: Mis ravim on Karvea ja milleks seda kasutatakse
English: Other medicines and Karvea
Estonian: Muud ravimid ja Karvea
English: Such conditions should be corrected before the administration of Karvea.
Estonian: Sellised seisundid tuleb korrigeerida enne ravi alustamist Karvea'ga.
English: Karvea belongs to a group of medicines known as angiotensin-II receptor antagonists.
Estonian: Karvea kuulub ravimite gruppi, mida tuntakse angiotensiin-II retseptori antagonistidena.
English: IDNT was a double blind, controlled, morbidity and mortality trial comparing Karvea, amlodipine and placebo.
Estonian: IDNT oli topeltpime, kontrollgrupiga, haigestumuse ja suremuse uuring, kus võrreldi Karvea't, amlodipiini ja platseebot.